Views: 0 Author: Site Editor Publish Time: 2026-09-08 Origin: Site
Choosing an aged garlic extract supplement manufacturer should begin with evidence, not unit price. The strongest candidates can show how the approved aged garlic ingredient is defined, how raw-material lots are controlled, how product specifications connect to batch release, how the dosage form is evaluated, and how changes are handled after approval.
A useful shortlist test is simple: Can the manufacturer connect ingredient → specification → production record → finished batch → label without changing the meaning of the product along the way?
Once a brand has decided to launch an aged garlic extract product, the manufacturer-selection question is narrower than product development: which supplier can repeatedly manufacture the approved product and provide the evidence needed to support that decision?
That makes manufacturer selection different from comparing catalog pages. A quotation can show price, package count and commercial terms. It cannot by itself show whether two suppliers are quoting the same aged garlic preparation, whether their quality systems control the same specifications, whether a dosage-form proposal is technically workable, or whether changes will be communicated before they affect a commercial batch.
Price belongs after these gates, not before them. Once two candidates are demonstrably quoting the same product and quality scope, unit cost becomes useful. Before that, a lower quote may simply reflect a different ingredient, testing plan, packaging assumption or documentation package.
The first supplier comparison should be made at the raw-material definition, because “garlic extract” and “aged garlic extract” are not sufficient procurement specifications by themselves. The approved ingredient should be defined in enough detail that purchasing, formulation and quality teams know which commercial material belongs in the project.
A buyer needs a sufficiently controlled commercial ingredient definition. That does not automatically mean the manufacturer or upstream supplier must disclose every proprietary processing condition. Evaluate whether the approved material can be identified, specified, tested and controlled consistently—not whether the supplier is willing to disclose its entire manufacturing know-how.
If the approved project specifies aged garlic extract, replacing it with another garlic preparation should be treated as a product change that requires technical and labeling review. The commercial agreement can make that expectation explicit by requiring prior review of changes to the approved raw-material source, specification or preparation that could affect the finished product.
For a deeper explanation of how aged garlic differs from other garlic preparations, see our aged garlic extract vs garlic extract guide. Manufacturer selection should begin after that preparation identity is understood.
Manufacturer quotes become difficult to compare when one supplier discusses a concentration ratio, another discusses a garlic-equivalent figure and another quotes an actual extract quantity. All can be valid numbers, but they describe different things.
Describes the relationship between starting botanical material and extract under a defined basis.
Expresses the starting-garlic amount represented under the stated extraction basis.
The quantity of commercial extract used in the approved finished formula.
The complete internal formulation, which may include extract plus carriers, excipients or other actives.
Ask each candidate to state the actual extract amount used in the proposed serving or dosage unit, the extract-ratio basis, any original-garlic equivalent used in commercial communication, and the total fill if it affects dosage-form feasibility. Do not compare quotes using “15:1” alone.
For U.S. Supplement Facts, a dried botanical extract from which the solvent has been removed is declared by the weight of the dried extract. An original-herb equivalent or concentration ratio can provide additional context, but it should not replace the required quantitative amount of the dried extract.
A manufacturer should be able to connect the aged garlic component received at the facility with the finished batches that used it. Under 21 CFR Part 111, incoming components are controlled through receiving examination, quarantine, representative sampling, quality-control review and lot identification.
For a component that is a dietary ingredient, confirm that the manufacturer has an appropriate identity-verification approach before use.
Ask how upstream suppliers are evaluated and how supplier documentation is reviewed, qualified and periodically reconfirmed where supplier COAs are relied upon.
Confirm that incoming lots receive unique identifiers that connect supplier, receipt status and disposition to the dietary supplement batches manufactured from them.
The important distinction is that a supplier certificate of analysis is not the same thing as the manufacturer's entire incoming-control system. For dietary-ingredient identity, Part 111 generally requires at least one appropriate identity test or examination before use unless the specific exemption process applies. For other applicable component specifications, reliance on a supplier COA is allowed only when the regulatory conditions for supplier qualification and COA reliability are met.
A specification defines what has to be true for a material, process stage or finished batch to be acceptable. A COA or other release document reports selected results. Manufacturer evaluation should confirm that those documents belong to one controlled system rather than treating the COA as the specification itself.
Some controls may be documented in component records, in-process records, batch records or other quality documentation rather than printed on the commercial COA. The buyer's job is to define the document package needed for the project and confirm that it connects to the approved release specification—not to force every internal control into one certificate.
If your project is a softgel, manufacturer evaluation has to go beyond “Do you make softgels?” A softgel is a connected formulation system in which the internal fill, shell, unit size and packaging have to be evaluated together.
MINGYAN's softgel manufacturing process evaluates ingredient concentration, carrier system where applicable, fill viscosity, active distribution, shell compatibility, capsule size and packaging as connected development variables. The same framework should be used when comparing any aged garlic softgel manufacturer.
Ask whether the aged garlic ingredient will be dissolved, dispersed, suspended or otherwise incorporated into the proposed fill. Do not assume the physical state from the word “softgel.”
The manufacturer should be able to explain how viscosity, particle behavior or distribution is evaluated when those attributes are relevant to the selected formula.
Confirm that shell selection follows the actual formula and target market rather than being treated as an independent cosmetic decision.
Manufacturer competence is demonstrated by a technically coherent development plan and measurable product controls. Buyers do not need proprietary encapsulation settings to evaluate whether the supplier understands fill behavior, shell compatibility, serving configuration and finished-product requirements.
A sample shows that a product can be made once. A controlled manufacturing record is part of what allows the process to be repeated.
Under 21 CFR Part 111, a manufacturer prepares and follows a master manufacturing record for each unique formulation and batch size. Each actual batch also has a batch production record containing complete information relating to its production and control and following the applicable master manufacturing record.
Includes formulation/component quantities, specifications, relevant process controls, packaging and representative label information.
Contains batch identifiers, component identifiers, equipment information, actual yields, monitoring/test results and quality-control review or disposition information.
For example, agreed COA, release documentation, testing records, traceability information or other project-specific documents.
A supplier may treat full manufacturing records as confidential. During qualification, a brand can still ask how the record system is structured, what information is available through audit or controlled review, and which batch-level documents will be supplied contractually. Where appropriate, redacted examples or summaries can be discussed subject to confidentiality arrangements.
Part 111 does not mean that every conceivable specification must be independently tested on every finished batch. The manufacturer establishes product specifications and uses an appropriate verification strategy—including selected finished-batch tests or examinations and supporting component/in-process controls—to demonstrate that the production system is producing conforming dietary supplements.
During manufacturer evaluation, ask which finished-product specifications are directly verified, which are supported by component or in-process controls, how sampling is determined, and what the customer receives as evidence of release. The answer should reflect the actual aged garlic product rather than a testing package copied unchanged from an unrelated supplement.
U.S. dietary-supplement labeling does not generally require an expiration date. If a brand chooses to place an expiration, best-by or similar date on the product, the date should be supported by valid data. Ask what stability data or testing support is available for the actual formula and commercial packaging rather than assuming a generic shelf life from another product.
For a dried botanical extract sold in the United States, the quantitative Supplement Facts amount is the dried-extract weight, not the weight of the original garlic represented by an equivalent statement. This makes artwork review part of supplier evaluation: the technical team should be able to connect the approved formula to Serving Size, actual dietary-ingredient quantity and the final label.
For qualifying U.S. structure/function and related claims under section 403(r)(6), the manufacturer, packer or distributor marketing the claim must meet the applicable requirements, including substantiation that the claim is truthful and not misleading, the required disclaimer and notification to FDA no later than 30 days after first marketing the supplement with the claim. Private-label parties should agree who handles these responsibilities before final artwork is approved.
Manufacturer selection should consider what happens after the first successful order. Raw-material sources change. Specifications are revised. Packaging components become unavailable. Equipment and processes may be updated. A reliable supply relationship needs a defined route for reviewing changes that could affect the approved product.
Part 111 requires quality-control personnel to approve or reject processes, specifications, written procedures, controls, tests, examinations and modifications that may affect identity, purity, strength or composition. A buyer-facing change-notification agreement is the commercial layer placed on top of that internal control system.
Avoid writing a change clause so broadly that every harmless internal adjustment requires customer approval. Focus it on changes that can affect the agreed ingredient, formulation, product specification, label, packaging, quality attributes or regulatory position.
For custom projects, we can evaluate formula strength, dosage-form details, shell, count, packaging and label according to the target market and confirmed formulation. The public product configuration is a project reference; it does not replace the raw-material and finished-product specifications agreed for an individual brand.
Our OEM / ODM process covers formula selection or technical review, sampling, dosage-form development, manufacturing, packaging, quality coordination and delivery support. Manufacturer qualification questions can therefore be raised before the project moves into sampling or bulk production.
Use the same scoring rule for every candidate: 0 = not demonstrated, 1 = partially demonstrated, 2 = clearly demonstrated with relevant evidence. The score is not a substitute for qualification, but it prevents an attractive quote or sales presentation from dominating the comparison.
Send the same core request to every shortlisted manufacturer. Leave genuinely open technical decisions marked as TBD so candidates can show how they would solve them.
Destination market / sales channel: ______________________________
Approved aged garlic preparation / reference: ______________________________
Botanical identity / plant part: ______________________________
Marker + target / range + method: ______________________________
Extract ratio + basis: ______________________________
Actual extract amount: ______________________________ / TBD
Garlic-equivalent statement, if used: ______________________________
Dosage form: □ softgel □ capsule □ request technical recommendation
Serving Size / units per serving: ______________________________
Package count / packaging: ______________________________
Desired label claims for review: ______________________________
Finished-product specification / testing requirements: ______________________________
Required buyer-facing batch documents: ______________________________
Change-notification expectations: ______________________________
Estimated first order / annual range: ______________________________
Open technical items: ______________________________
1. How do you qualify and approve the upstream supplier of the aged garlic ingredient proposed for this project?
2. How will dietary-ingredient identity be verified before the component is used?
3. How are incoming lots identified and traced to finished batches?
4. Which specifications define component acceptance and finished-batch release?
5. Which test results or release information will appear in the customer document package?
6. If the project is a softgel, how will the actual aged garlic ingredient be incorporated and evaluated with the shell system?
7. What records are maintained for each commercial batch, and what evidence can be reviewed during qualification or audit?
8. What stability support is available for the proposed formula and commercial packaging?
9. How is final artwork checked against the approved product specification?
10. Which raw-material, formula, packaging or process changes trigger customer notification or approval?
Start with the ingredient definition and the product specification, not unit price. Confirm that each candidate is quoting the same aged garlic preparation, concentration basis, actual extract amount, dosage form, serving configuration and quality-document scope before commercial prices are compared.
Ask how the commercial ingredient is defined, how its supplier is qualified, which identity-verification approach is used, how each incoming lot is approved and how the lot identifier is connected to the finished batch. Do not rely on the words “aged garlic” on a sales sheet alone.
Not necessarily. Some attributes may be controlled through component records, in-process controls, batch records or other quality documentation. Define which finished-product test results and release information you need on the buyer-facing COA or document package and confirm how those documents connect to the approved product specification.
A batch production record is a required manufacturing record, but it can contain proprietary or confidential information and is not automatically a customer deliverable. During qualification, ask how the record system works, what can be reviewed under appropriate confidentiality arrangements and which batch-level documents will be supplied for your project.
No. An extract ratio describes a concentration relationship. It does not by itself tell you the actual dried-extract amount in the serving, the marker content, finished-product quality or clinical value. Compare the complete specification rather than ranking suppliers by ratio alone.
A strong softgel manufacturer evaluates the actual botanical ingredient together with the complete fill system, active loading, physical behavior, shell compatibility, unit size, serving configuration and packaging. The supplier should be able to explain why the proposed dosage-form system is suitable without relying on generic claims that every botanical extract behaves the same way.
Not as a general FDA labeling requirement. If an expiration, best-by or similar date is used, it should be supported by valid data. Ask what stability support exists for the actual formula and commercial packaging before a shelf-life statement is placed on the label.
Normalize the specification first: same aged garlic ingredient, same ratio basis, same actual extract amount, same dosage form, same serving configuration, same package count, same testing scope and same customer document requirements. Only then compare unit price and commercial terms.
Tell us the target market, aged garlic ingredient or reference product, dosage form, serving target, packaging, estimated quantity, testing expectations and batch documents you require. We can review the project scope and clarify which items are ready for quotation and which still need technical confirmation.
Send Your Manufacturer Checklist →
